References in periodicals archive ?
Morris brings to ImmunoGen nearly twenty years of experience in the development of anticancer compounds, including experience with registration clinical trials, regulatory approvals, pharmacovigilance, and medical affairs support for marketed products.
There are now ten TAP compounds in clinical development, of which three are wholly owned by ImmunoGen.
Trastuzumab emtansine uses ImmunoGen's TAP technology with Roche's trastuzumab antibody and is in global development by Roche under an agreement between ImmunoGen and Genentech, a member of the Roche Group.